GLP‑1 story widens — pill approved
Regulatory and reporting updates show GLP‑1 drugs moving beyond injections: the FDA has approved oral semaglutide as the first GLP‑1 pill for weight loss. (ajmc.com) At the same time, coverage notes that some people may see benefits like improved liver health even without big weight loss, while states and insurers are already changing coverage and users report side‑effects on social forums. ( )
The Food and Drug Administration has approved oral semaglutide for chronic weight management, putting a once-daily Wegovy pill on the market after years of weekly injections. (ajmc.com) The new tablet extends the Wegovy brand beyond shots and carries the same basic use: adults with obesity, or adults who are overweight with at least one weight-related condition, alongside diet and exercise. The Food and Drug Administration label also says the tablet is indicated to reduce major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. (accessdata.fda.gov) In Novo Nordisk’s OASIS 4 trial, adults taking 25 milligrams of oral semaglutide lost about 13.6% of body weight at 64 weeks on average, according to the approval coverage and prescribing information. Novo Nordisk said after the December 2025 approval that it planned a United States launch in early January 2026. (ajmc.com) (novo-pi.com) Glucagon-like peptide-1 drugs copy a gut hormone that helps people feel full, slows stomach emptying, and improves blood sugar control. The pill matters because it gives patients who avoid injections a new way to take the same ingredient, semaglutide. (cedars-sinai.org) (wegovy.com) The science story is widening at the same time. A Cell Metabolism study published April 14 found semaglutide improved liver health in mouse models through liver sinusoidal endothelial cells, a specific type of blood-vessel cell in the liver, even when weight loss was not driving the effect. (cell.com) (cnn.com) Coverage is tightening in parts of the United States even as the list of possible benefits grows. The Guardian reported on April 14 that some states and public employers have started restricting or ending coverage for glucagon-like peptide-1 weight-loss drugs as spending climbs. (theguardian.com) Safety questions are widening, too, mostly around side effects patients describe after starting treatment. Fox News reported this week on a study and online reports about issues including nausea, vomiting, and other gastrointestinal problems, which are already listed in Wegovy prescribing information as common adverse reactions. (foxnews.com) (novo-pi.com) The result is a market that now looks less like a single weight-loss product and more like a fast-expanding treatment category with new formats, new claims, and new fights over who pays. The next phase is likely to turn on access as much as on efficacy. (ajmc.com) (theguardian.com)
